EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG) [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
extension application for Tryngolza® (olezarsen) for the treatment of adult patients with severe hypertriglyceridemia (sHTG) =880 mg/dL (=10 mmol/L). Patients with elevated triglyceride levels have substantially higher risks of all-cause mortality, atherosclerotic cardiovascular events, and acute pancreatitis [1] The submission is supported by results from the pivotal Phase 3 CORE and CORE2 studies , which were published in the New England Journal of Medicine in 2025 [2] "Tryngolza is the only pharmacological therapy to demonstrate a reduction in the risk of acute pancreatitis in patients with severe hypertriglyceridemia. If approved, it could offer an important therapeutic option to help prevent this life-threatening condition, which can place a significant burden on patients due to frequent hospitalisations, intensive treatment, persistent symptoms and reduced quality of life," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. "Sobi's
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- FDA Priority Review Puts Ionis Zilganersen At Center Of Rare-Disease Story [Yahoo! Finance]Yahoo! Finance
- Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals (IONS) had its price target raised by Barclays PLC from $95.00 to $106.00. They now have an "overweight" rating on the stock.MarketBeat
- Ionis Pharmaceuticals (IONS) had its price target raised by Needham & Company LLC from $103.00 to $105.00. They now have a "buy" rating on the stock.MarketBeat
- Ionis Pharmaceuticals (IONS) had its price target raised by HC Wainwright from $110.00 to $120.00. They now have a "buy" rating on the stock.MarketBeat
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 3/31/26 - Form 144
- IONS's page on the SEC website